Sponsor: 
Sanofi Pasteur Pty Ltd
Administration route: 
Intramuscular injection
Vaccine group: 
Combination vaccines

Registered for primary immunisation in infants aged 2–12 months and as a booster in children aged 15 months to 6 years.

DTPa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine

Each 0.5 mL monodose vial contains:

  • ≥30 IU diphtheria toxoid
  • ≥40 IU tetanus toxoid
  • 20 µg pertussis toxoid
  • 20 µg filamentous haemagglutinin
  • 3 µg pertactin
  • 5 µg pertussis fimbriae types 2 and 3
  • 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
  • 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
  • 32 D-antigen units inactivated poliovirus type 3 (Saukett)
  • 1.5 mg aluminium phosphate
  • ≤50 ng bovine serum albumin
  • 0.6% v/v phenoxyethanol

Also contains traces of:

  • formaldehyde
  • glutaraldehyde
  • polysorbate 80
  • polymyxin
  • neomycin

For full details, refer to the product information and consumer medicine information sheets for Quadracel vaccine available on the TGA website.

Related diseases: 
Diphtheria
Tetanus
Pertussis (whooping cough)
Poliomyelitis

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018

Definitions

DTPa
diphtheria-tetanus-acellular pertussis vaccine
IPV
inactivated poliomyelitis vaccine
IU
international units